Machine to Machine (M2M) communication is an enormous potential value to business by providing the basis for integrated services between billions of machines and objects. SGS is poised to assist the industry to meet the potential and challenges of the M2M world which require the development of a range of new information, telecommunication and electronics technologies that must be standardized and interconnected.
The cleaning validation for the twin screw extruder in the Development & Transfer Center of Rottendorf Pharma GmbH in Ennigerloh has successfully been completed. With this, the complete equipment of the Center which was newly built in 2009 can be used under GMP conditions as well as under FDA conditions.
The already wide range of equipment for the production of clinical trial samples and small-scale batches is therewith extended by another interesting technology. Hot-melt extrusion
In 2009, the EU Consumer Report already revealed that one in three Christmas light strings is defective. In addition, China-s low-tech lighting products, currently flooding the European market, may also harbor safety-related faults. Safety tests by SGS E&E can prevent the proliferation of defective lighting.
Frankfurt/London, December 15th 2010 – Targacom Advisory in Frankfurt and Revolution Public Relations Ltd. in London have teamed up to provide strategic advisory services to clients in the real estate investment industry. The primary clientele is institutional investors, family offices and real estate service providers in the UK and Germany who are either currently, or are about to become, active on in each other-s respective markets.
Revolution Public Relations Ltd. specialises in communicat
Brazil has passed Settlement CONAMA no. 401/08 into law as of July 2009, tightening controls on the composition of batteries and cells and in particular on their final disposal.
AiCuris announced today that the last subject has completed their Phase-II trial "A double-blind randomized placebo controlled dose-finding trial to investigate different doses of a new antiviral drug in subjects with genital HSV Type 2 infection".
The trial has been completed two months earlier than planned. Indeed, in the later stages of the trial, enrolment had to be restricted as the number of subjects was higher than the number that was required to be enrolled according t
Results from a series of studies presented this week at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida highlight the value of high-throughput sequencing for in-depth characterization of blood cancers, including leukemia and other hematological malignancies. The research studies used the Genome Sequencer FLX and GS Junior Systems from 454 Life Sciences to perform targeted resequencing of known cancer-related genes, such as KRAS, RUNX1, EZH2, and TET2, in order to dete
